Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Metallomics in drug development : characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS. / Nguyen, Trinh Thi Nhu Tam; Ostergaard, Jesper; Stürup, Stefan; Gammelgaard, Bente.

In: Analytical and Bioanalytical Chemistry, Vol. 405, No. 6, 2013, p. 1845-1854.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nguyen, TTNT, Ostergaard, J, Stürup, S & Gammelgaard, B 2013, 'Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS', Analytical and Bioanalytical Chemistry, vol. 405, no. 6, pp. 1845-1854. https://doi.org/10.1007/s00216-012-6355-2

APA

Nguyen, T. T. N. T., Ostergaard, J., Stürup, S., & Gammelgaard, B. (2013). Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS. Analytical and Bioanalytical Chemistry, 405(6), 1845-1854. https://doi.org/10.1007/s00216-012-6355-2

Vancouver

Nguyen TTNT, Ostergaard J, Stürup S, Gammelgaard B. Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS. Analytical and Bioanalytical Chemistry. 2013;405(6):1845-1854. https://doi.org/10.1007/s00216-012-6355-2

Author

Nguyen, Trinh Thi Nhu Tam ; Ostergaard, Jesper ; Stürup, Stefan ; Gammelgaard, Bente. / Metallomics in drug development : characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS. In: Analytical and Bioanalytical Chemistry. 2013 ; Vol. 405, No. 6. pp. 1845-1854.

Bibtex

@article{c00b8e7fe29a461390c9b1bb75a7c414,
title = "Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS",
abstract = "A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation. The effect of human plasma matrix on the analysis of liposome-encapsulated cisplatin and intact cisplatin was studied. The presence of 1 % of dextran and 4 mM of sodium dodecyl sulfate in HEPES buffer was demonstrated to be effective in improving the separation of liposomes and cisplatin bound to proteins in plasma. A detection limit of 41 ng/mL of platinum and a precision of 2.1 % (for 10 µg/mL of cisplatin standard) were obtained. Simultaneous measurements of phosphorous and platinum allows the simultaneous monitoring of the liposomes, liposome-encapsulated cisplatin, free cisplatin and cisplatin bound to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before and will improve characterization of liposomal drugs during drug development and in studies on kinetics.",
author = "Nguyen, {Trinh Thi Nhu Tam} and Jesper Ostergaard and Stefan St{\"u}rup and Bente Gammelgaard",
year = "2013",
doi = "10.1007/s00216-012-6355-2",
language = "English",
volume = "405",
pages = "1845--1854",
journal = "Analytical and Bioanalytical Chemistry",
issn = "1618-2642",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Metallomics in drug development

T2 - characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS

AU - Nguyen, Trinh Thi Nhu Tam

AU - Ostergaard, Jesper

AU - Stürup, Stefan

AU - Gammelgaard, Bente

PY - 2013

Y1 - 2013

N2 - A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation. The effect of human plasma matrix on the analysis of liposome-encapsulated cisplatin and intact cisplatin was studied. The presence of 1 % of dextran and 4 mM of sodium dodecyl sulfate in HEPES buffer was demonstrated to be effective in improving the separation of liposomes and cisplatin bound to proteins in plasma. A detection limit of 41 ng/mL of platinum and a precision of 2.1 % (for 10 µg/mL of cisplatin standard) were obtained. Simultaneous measurements of phosphorous and platinum allows the simultaneous monitoring of the liposomes, liposome-encapsulated cisplatin, free cisplatin and cisplatin bound to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before and will improve characterization of liposomal drugs during drug development and in studies on kinetics.

AB - A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation. The effect of human plasma matrix on the analysis of liposome-encapsulated cisplatin and intact cisplatin was studied. The presence of 1 % of dextran and 4 mM of sodium dodecyl sulfate in HEPES buffer was demonstrated to be effective in improving the separation of liposomes and cisplatin bound to proteins in plasma. A detection limit of 41 ng/mL of platinum and a precision of 2.1 % (for 10 µg/mL of cisplatin standard) were obtained. Simultaneous measurements of phosphorous and platinum allows the simultaneous monitoring of the liposomes, liposome-encapsulated cisplatin, free cisplatin and cisplatin bound to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before and will improve characterization of liposomal drugs during drug development and in studies on kinetics.

U2 - 10.1007/s00216-012-6355-2

DO - 10.1007/s00216-012-6355-2

M3 - Journal article

C2 - 23052859

VL - 405

SP - 1845

EP - 1854

JO - Analytical and Bioanalytical Chemistry

JF - Analytical and Bioanalytical Chemistry

SN - 1618-2642

IS - 6

ER -

ID: 44054134